NEW YORK, April 11, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on SLDB, MDCO, VSAR, and ZTS which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com covers the Generic Drugs space, which comprises manufacturers of medications
On Tuesday, shares in Cambridge, Massachusetts headquartered Solid Biosciences Inc. recorded a trading volume of 317,271 shares. The stock ended at $9.97, rising 1.22% from the last trading session. The Company's shares are trading below their 50-day moving average by 52.25%. Furthermore, shares of Solid Biosciences, which engages in identifying and developing various therapies for duchenne muscular dystrophy in the US, have a Relative Strength Index (RSI) of 34.00.
On March 29th, 2018, Solid Biosciences reported its financial results for the year ended December 31st, 2017. Net loss for the full year was $53.2 million; R&D expenses were $39.9 million; and G&A expenses were $15.0 million. As of December 31st, 2017, cash, cash equivalents, and available-for-sale securities were $69.1 million. Get the full research report on SLDB for free by clicking below at:
Parsippany, New Jersey-based The Medicines Co.'s stock finished yesterday's session 2.94% higher at $30.44 with a total trading volume of 1.28 million shares. The Company's shares have gained 12.66% over the previous three months. The stock is trading below its 50-day moving average by 6.11%. Furthermore, shares of Medicines Co., which provides medicines to treat acute and intensive care patients, have an RSI of 42.62.
On March 27th, 2018, Medicines Co. announced the appointment of Christopher Visioli as CFO and Treasurer, effective immediately. Mr. Visioli succeeds William B. O'Connor, who is retiring after serving as Chief Accounting Officer and then CFO for a total of 13 years. Mr. O'Connor will remain as an advisor through 2018, assisting Mr. Visioli in transition and completing the close-out of the Company's non-core businesses and products. The free technical report on MDCO can be accessed at:
At the close of trading on Tuesday, shares in Menlo Park, California headquartered Versartis Inc. rose 1.59%, ending the day at $1.60. The stock recorded a trading volume of 852,445 shares, which was above its three months average volume of 514,560 shares. The Company's shares are trading 8.39% below their 50-day moving average. Moreover, shares of Versartis, which operates as an endocrine-focused biopharmaceutical company in the US, have an RSI of 43.41. Sign up for free on Wall St. Equities and claim the latest report on VSAR at:
Parsippany, New Jersey headquartered Zoetis Inc.'s shares ended the day 1.49% higher at $83.09 with a total trading volume of 2.34 million shares. The stock has gained 11.92% over the previous three months and 58.15% over the past year. The Company's shares are trading 3.41% above their 50-day moving average and 18.61% above their 200-day moving average. Additionally, shares of Zoetis, which discovers, develops, manufactures, and markets veterinary vaccines and medicines in the US and internationally, have an RSI of 55.55.
On March 19th, 2018, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'.
On March 29th, 2018, Zoetis announced that it will host a webcast and conference call on May 02nd, 2018, at 8:30 a.m. ET. CEO, Juan Ramón Alaix, and Executive Vice President and CFO, Glenn David, will review the Company's Q1 2018 financial results and respond to questions from financial analysts during the call. See the free research coverage on ZTS at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number:+21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-generic-drugs-stocks----solid-biosciences-medicines-co-versartis-and-zoetis-300627900.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!